CureVac NV (WBO:CVAC) Total Tax Payable : €0.64 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Total Tax Payable?

CureVac NV's Total Tax Payable for the quarter that ended in Sep. 2023 was €0.64 Mil.

CureVac NV's quarterly Total Tax Payable increased from Mar. 2023 (€0.61 Mil) to Jun. 2023 (€0.63 Mil) and increased from Jun. 2023 (€0.63 Mil) to Sep. 2023 (€0.64 Mil).

CureVac NV's annual Total Tax Payable declined from Dec. 2020 (€12.66 Mil) to Dec. 2021 (€1.66 Mil) and declined from Dec. 2021 (€1.66 Mil) to Dec. 2022 (€1.53 Mil).

CureVac NV Total Tax Payable Historical Data

The historical data trend for CureVac NV's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Total Tax Payable Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Tax Payable

0.22

0.11

12.66

1.66

1.53

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Tax Payable	Get a 7-Day Free Trial														0.59	1.53	0.61	0.63	0.64

CureVac NV Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

CureVac NV Total Tax Payable Related Terms

Thank you for viewing the detailed overview of CureVac NV's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.